← Leaderboards
Robert A Lafyatis
Boston University Medical Campus
$10,905,922
Attributed
$13,398,890
Total exposure
19
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$37,760,785 · 22
By mechanism
P50$26,476,207 · 8
R01$3,594,094 · 2
P30$3,128,982 · 1
U01$2,993,152 · 2
R21$931,935 · 2
R61$387,696 · 1
Top collaborators
- Panagiotis V Benos4 shared
- Toren Finkel4 shared
- Ana L Mora4 shared
- Mauricio Rojas4 shared
- Robert W Simms2 shared
- Harrison W Farber1 shared
- Paul M Hassoun1 shared
- Daniel J Kass1 shared
Most similar at Boston University Medical Campus
Same institution · by research overlap
- Maria Trojanowska$16,742,564
- Robert W Simms$2,168,460
Others in their field
Top investigators on “Systemic Scleroderma”
- Eugene W. St Clair · Duke University$24,182,181
- John Varga · University Of Illinois At Chicago$13,781,985
- Carol A Feghali-Bostwick · University Of Pittsburgh At Pittsburgh$11,771,501
- Judith A James · Oklahoma Medical Research Foundation$11,331,322
- Robert M Elashoff · John Wayne Cancer Institute$10,394,671
- Maria Trojanowska · Boston University Medical Campus$10,085,547
Research focus
Systemic SclerodermaPathogenesisLungSkinCellsLung DiseasesSkin DisorderInterstitial Lung DiseasesFibroblastsFibrosisBlood VesselsMolecularPathway InteractionsGene ExpressionGenesBiological MarkersProgramsResearch PersonnelTranslational StudyPulmonary Arterial HypertensionMyofibroblastUniversitiesScientistNovel Therapeutics
Grant awards (87)
Clinical-Translational Studies in Skin, Lung, and Vascular Complications in Systemic Sclerosis$1,406,939
P50 · FY2025 · AR · contact PI
E-Box Accessibility in Myofibroblasts in Pulmonary Fibrosis$773,440
R01 · FY2025 · HL
Administrative Core$234,491
P50 · FY2025 · AR · contact PI
Cell epigenetics & communication in systemic sclerosis and localized scleroderma skin disease$234,490
P50 · FY2025 · AR · contact PI
Pathways regulating profibrotic macrophages in a novel explant model of systemic sclerosis-associated interstitial lung disease$148,064
R21 · FY2025 · AR · contact PI
Clinical-Translational Studies in Skin, Lung, and Vascular Complications in Systemic Sclerosis$147,840
P50 · FY2025 · AR · contact PI
Clinical-Translational Studies in Skin, Lung, and Vascular Complications in Systemic Sclerosis$1,563,264
P50 · FY2024 · AR · contact PI
Cell epigenetics & communication in systemic sclerosis and localized scleroderma skin disease$302,100
P50 · FY2024 · AR · contact PI
Pathways regulating profibrotic macrophages in a novel explant model of systemic sclerosis-associated interstitial lung disease$199,496
R21 · FY2024 · AR · contact PI
Administrative Core$190,800
P50 · FY2024 · AR · contact PI
Molecular Basis for Altered Natural Killer Cells in Systemic Sclerosis associated-Interstitial Lung Disease$147,840
P50 · FY2024 · AR · contact PI
Clinical-Translational Studies in Skin, Lung, and Vascular Complications in Systemic Sclerosis$1,565,814
P50 · FY2023 · AR · contact PI
Cell epigenetics & communication in systemic sclerosis and localized scleroderma skin disease$302,100
P50 · FY2023 · AR · contact PI
Administrative Core$190,800
P50 · FY2023 · AR · contact PI
Clinical-Translational Studies in Skin, Lung, and Vascular Complications in Systemic Sclerosis$1,534,755
P50 · FY2022 · AR · contact PI
Mapping Age-Related Changes in the Lung$543,214
U01 · FY2022 · HL
Cell epigenetics & communication in systemic sclerosis and localized scleroderma skin disease$302,100
P50 · FY2022 · AR · contact PI
Administrative Core$159,000
P50 · FY2022 · AR · contact PI
Translational studies for identifying and targeting novel pathways in systemic sclerosis pathogenesis$1,356,315
P50 · FY2021 · AR · contact PI
Mapping Age-Related Changes in the Lung$558,954
U01 · FY2021 · HL
Project 1: Systemic Sclerosis Skin Biomarkers & Therapeutics$221,464
P50 · FY2021 · AR · contact PI
Administrative Core$158,186
P50 · FY2021 · AR · contact PI
Translational studies for identifying and targeting novel pathways in systemic sclerosis pathogenesis$69,372
P50 · FY2021 · AR · contact PI
NIAMS: Center for Research Translation (CORT)$14,186
P50 · FY2021 · AR · contact PI
Translational studies for identifying and targeting novel pathways in systemic sclerosis pathogenesis$1,300,164
P50 · FY2020 · AR · contact PI
Mapping Age-Related Changes in the Lung$626,000
U01 · FY2020 · HL
Project 1: Systemic Sclerosis Skin Biomarkers & Therapeutics$221,464
P50 · FY2020 · AR · contact PI
Administrative Core$158,185
P50 · FY2020 · AR · contact PI
Translational studies for identifying and targeting novel pathways in systemic sclerosis pathogenesis$1,367,116
P50 · FY2019 · AR · contact PI
Mapping Age-Related Changes in the Lung$626,000
U01 · FY2019 · HL
Open chromatin and transcriptional regulation of dermal myofibroblasts in SSc$387,696
R61 · FY2019 · AR · contact PI
Project 1: Systemic Sclerosis Skin Biomarkers & Therapeutics$221,464
P50 · FY2019 · AR · contact PI
Administrative Core$158,185
P50 · FY2019 · AR · contact PI
Dimethyl Fumarate In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension$138,548
R21 · FY2019 · AR · contact PI
International Workshop on Scleroderma Research$15,000
R13 · FY2019 · AR · contact PI
Translational studies for identifying and targeting novel pathways in systemic sclerosis pathogenesis$1,310,592
P50 · FY2018 · AR · contact PI
Project 1: Systemic Sclerosis Skin Biomarkers & Therapeutics$212,657
P50 · FY2018 · AR · contact PI
Dimethyl Fumarate In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension$208,987
R21 · FY2018 · AR · contact PI
Administrative Core$149,379
P50 · FY2018 · AR · contact PI
NIAMS: Center for Research Translation (CORT)$75,771
P50 · FY2018 · AR · contact PI
International Workshop on Scleroderma Research$1
R13 · FY2018 · AR · contact PI
Translational studies for identifying and targeting novel pathways in systemic sclerosis pathogenesis$1,309,324
P50 · FY2017 · AR · contact PI
Dimethyl Fumarate In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension$236,840
R21 · FY2017 · AR · contact PI
Administrative Core$187,047
P50 · FY2017 · AR · contact PI
Project 1: Systemic Sclerosis Skin Biomarkers & Therapeutics$187,046
P50 · FY2017 · AR · contact PI
International Workshop on Scleroderma Research$15,000
R13 · FY2017 · AR · contact PI
NIAMS: CORT$1,622,952
P50 · FY2015 · AR
Rheumatic Diseases Research Core Centers$607,504
P30 · FY2015 · AR
Project 1 Biomarkers of disease activity and progression in systemic sclerosis$285,007
P50 · FY2015 · AR · contact PI
Innate immunity in dermal fibrosis and systemic sclerosis$221,574
R01 · FY2015 · AR · contact PI
Innate immunity in dermal fibrosis and systemic sclerosis$132,795
R01 · FY2015 · AR · contact PI
International Workshop on Scleroderma Research$25,000
R13 · FY2015 · AR · contact PI
NIAMS: CORT$1,622,905
P50 · FY2014 · AR · contact PI
Rheumatic Diseases Research Core Centers$615,504
P30 · FY2014 · AR · contact PI
Innate immunity in dermal fibrosis and systemic sclerosis$360,959
R01 · FY2014 · AR · contact PI
Project 1 Biomarkers of disease activity and progression in systemic sclerosis$285,018
P50 · FY2014 · AR · contact PI
NIAMS: CORT$1,541,891
P50 · FY2013 · AR · contact PI
Rheumatic Diseases Research Core Centers$598,562
P30 · FY2013 · AR · contact PI
Innate immunity in dermal fibrosis and systemic sclerosis$349,909
R01 · FY2013 · AR · contact PI
Project 1 Biomarkers of disease activity and progression in systemic sclerosis$280,424
P50 · FY2013 · AR · contact PI
International Workshop on Scleroderma Research$15,000
R13 · FY2013 · AR · contact PI
NIAMS: CORT$1,623,290
P50 · FY2012 · AR · contact PI
Rheumatic Diseases Research Core Centers$630,065
P30 · FY2012 · AR · contact PI
Innate immunity in dermal fibrosis and systemic sclerosis$368,251
R01 · FY2012 · AR · contact PI
Project 1 Biomarkers of disease activity and progression in systemic sclerosis$298,515
P50 · FY2012 · AR · contact PI
International Workshop on Scleroderma Research$15,000
R13 · FY2012 · AR · contact PI
NIAMS: CORT$1,652,583
P50 · FY2011 · AR · contact PI
Rheumatic Diseases Research Core Centers$677,347
P30 · FY2011 · AR · contact PI
Innate immunity in dermal fibrosis and systemic sclerosis$367,501
R01 · FY2011 · AR · contact PI
Project 1 Biomarkers of disease activity and progression in systemic sclerosis$303,372
P50 · FY2011 · AR · contact PI
Microarray biomarkers of disease activity and progression in systemic sclerosis$206,382
U01 · FY2009 · AR · contact PI
Altered elastogenesis by Tsk fibrillin-1 and in SSc$198,091
R01 · FY2009 · AR · contact PI
Tenth International Workshop on Scleroderma Research - August 2-6,2008, Cambridge$15,000
R13 · FY2009 · AR · contact PI
Microarray biomarkers of disease activity and progression in systemic sclerosis$206,382
U01 · FY2008 · AR · contact PI
Altered elastogenesis by Tsk fibrillin-1 and in SSc$198,091
R01 · FY2008 · AR · contact PI
Tenth International Workshop on Scleroderma Research - August 2-6,2008, Cambridge$20,000
R13 · FY2008 · AR · contact PI
Microarray biomarkers of disease activity and progression in systemic sclerosis$226,220
U01 · FY2007 · AR · contact PI
Altered elastogenesis by Tsk fibrillin-1 and in SSc$202,133
R01 · FY2007 · AR · contact PI
RITUXIMAB TREATMENT OF SCLERODERMA$17,016
M01 · FY2007 · RR · contact PI
Altered elastogenesis by Tsk fibrillin-1 and in SSc$208,170
R01 · FY2006 · AR · contact PI
RITUXIMAB TREATMENT OF SCLERODERMA - AN OPEN LABEL, PHASE I STUDY$24,321
M01 · FY2006 · RR · contact PI
International Workshop for Scleroderma Research$20,527
R13 · FY2006 · AR · contact PI
IMMUNE MEDIATED ALTERATIONS IN CONNECTIVE TISSUE$1,931
M01 · FY2006 · RR · contact PI
Altered elastogenesis by Tsk fibrillin-1 and in SSc$213,180
R01 · FY2005 · AR
RITUXIMAB TREATMENT OF SCLERODERMA - AN OPEN LABEL, PHASE I STUDY$6,998
M01 · FY2005 · RR
SWAP &SR PROTEIN REGULATION OF ALTERNATIVE SPLICING$53,566
P41 · FY2001 · RR
SWAP &SR PROTEIN REGULATION OF ALTERNATIVE SPLICING$4,359
P41 · FY2000 · RR